share_log

Evercore ISI Group Maintains Outperform on Heron Therapeutics, Lowers Price Target to $10

Benzinga ·  Mar 24, 2023 11:53

Evercore ISI Group analyst Shweta Khajuria maintains Heron Therapeutics (NASDAQ:HRTX) with a Outperform and lowers the price target from $15 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment